Skip to content

IRADIMED CORPORATION: 10-Q filed 2024-10-31

What IRADIMED CORPORATION reported in its quarterly report filed 2024-10-31 (fiscal Q3 2024): 51 published measures, 149 facts as tagged in accession 0001558370-24-014056.

This filing

Form
10-Q (quarterly report)
Filed
2024-10-31
Fiscal period
fiscal Q3 2024
Accession
0001558370-24-014056 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All IRADIMED CORPORATION filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-09-3094,246,761USD
At 2023-12-3192,156,098USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-09-3010,814,136USD
At 2023-12-3120,735,934USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-09-3083,432,625USD
At 2024-06-3079,671,489USD
At 2024-03-3176,121,462USD
At 2023-12-3171,420,164USD
At 2023-09-3074,568,000USD
At 2023-06-3068,998,442USD
At 2023-03-3164,339,915USD
At 2022-12-3173,672,987USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-09-3051,721,051USD
At 2023-12-3149,762,198USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-305,049,491USD92
2024-01-01 to 2024-09-3014,087,248USD274
2024-04-01 to 2024-06-304,901,224USD91
2024-01-01 to 2024-03-314,136,533USD91
2023-07-01 to 2023-09-305,067,180USD92
2023-01-01 to 2023-09-3012,653,090USD273
2023-04-01 to 2023-06-304,179,840USD91
2023-01-01 to 2023-03-313,406,070USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-01-01 to 2024-09-3019,637,394USD274
2023-01-01 to 2023-09-309,552,532USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2024-01-01 to 2024-09-305,214,859USD274
2023-01-01 to 2023-09-306,908,607USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2024-07-01 to 2024-09-3018,325,959USD92
2024-01-01 to 2024-09-3053,852,954USD274
2023-07-01 to 2023-09-3016,504,640USD92
2023-01-01 to 2023-09-3048,110,120USD273

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2024-07-01 to 2024-09-3018,325,959USD92
2024-01-01 to 2024-09-3053,852,954USD274
2023-07-01 to 2023-09-3016,504,640USD92
2023-01-01 to 2023-09-3048,110,120USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-11,918,484USD274
2023-01-01 to 2023-09-30-13,393,921USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-5,760,057USD274
2023-01-01 to 2023-09-30-7,374,351USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-09-3053,545,271USD
At 2023-12-3143,258,154USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-07-01 to 2024-09-3012,669,741shares92
2024-01-01 to 2024-09-3012,665,743shares274
2023-07-01 to 2023-09-3012,602,581shares92
2023-01-01 to 2023-09-3012,597,250shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-07-01 to 2024-09-3012,778,446shares92
2024-01-01 to 2024-09-3012,762,346shares274
2023-07-01 to 2023-09-3012,735,837shares92
2023-01-01 to 2023-09-3012,716,988shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-07-01 to 2024-09-300.4USD/shares92
2024-01-01 to 2024-09-301.11USD/shares274
2023-07-01 to 2023-09-300.4USD/shares92
2023-01-01 to 2023-09-301USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-07-01 to 2024-09-300.4USD/shares92
2024-01-01 to 2024-09-301.1USD/shares274
2023-07-01 to 2023-09-300.4USD/shares92
2023-01-01 to 2023-09-300.99USD/shares273

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2024-07-01 to 2024-09-301,368,830USD92
2024-01-01 to 2024-09-303,843,834USD274
2023-07-01 to 2023-09-301,341,352USD92
2023-01-01 to 2023-09-303,403,523USD273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-09-3014,155,985USD
At 2023-12-319,288,625USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-01-01 to 2024-09-301,867,701USD274
2023-01-01 to 2023-09-301,635,845USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-07-01 to 2024-09-305,789,120USD92
2024-01-01 to 2024-09-3016,164,510USD274
2023-07-01 to 2023-09-305,905,340USD92
2023-01-01 to 2023-09-3014,875,625USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-09-3074,286,227USD
At 2023-12-3176,001,112USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-09-308,063,010USD
At 2023-12-3116,327,306USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-09-301,400,544USD
At 2023-12-311,857,091USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2024-09-302,891,657USD
At 2023-12-312,519,053USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2024-09-3010,364,786USD
At 2023-12-3112,224,273USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-07-01 to 2024-09-308,402,586USD92
2024-01-01 to 2024-09-3025,424,512USD274
2023-07-01 to 2023-09-306,932,044USD92
2023-01-01 to 2023-09-3021,869,704USD273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2024-09-3011,251,549USD
At 2023-12-3112,821,194USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2024-07-01 to 2024-09-3014,191,706USD92
2024-01-01 to 2024-09-3041,589,022USD274
2023-07-01 to 2023-09-3012,837,384USD92
2023-01-01 to 2023-09-3036,745,329USD273

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2024-07-01 to 2024-09-304,134,253USD92
2024-01-01 to 2024-09-3012,263,932USD274
2023-07-01 to 2023-09-303,667,256USD92
2023-01-01 to 2023-09-3011,364,791USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-07-01 to 2024-09-30639,467USD92
2024-01-01 to 2024-09-302,261,596USD274
2023-07-01 to 2023-09-30452,555USD92
2023-01-01 to 2023-09-302,208,221USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-09-3012,669,912shares
At 2023-12-3112,660,313shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-09-3051,721,051USD
At 2023-12-3149,762,198USD
At 2023-09-3046,745,124USD
At 2022-12-3157,960,864USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-09-3029,886,087USD
At 2023-12-3128,160,745USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2024-09-30264,075USD
At 2023-12-312,043,043USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2024-09-30264,075USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2024-09-3018,616,142USD
At 2023-12-3113,358,460USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2024-09-304,460,157USD
At 2023-12-314,069,835USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2024-09-30184,213USD
At 2023-12-31181,449USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2024-09-30948,841USD
At 2023-12-311,193,447USD

Current contract liabilities

Consideration received before performance obligations are satisfied, often called deferred revenue. It is an obligation to deliver, not earned revenue or cash available.

PeriodValueUnitDays
At 2024-09-302,555,105USD
At 2023-12-312,570,407USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2024-07-01 to 2024-09-306,418,321USD92
2024-01-01 to 2024-09-3017,931,082USD274
2023-07-01 to 2023-09-306,408,532USD92
2023-01-01 to 2023-09-3016,056,613USD273

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2024-01-01 to 2024-09-3014,087,248USD274
2023-01-01 to 2023-09-3012,653,090USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-303,967,799USD92
2024-01-01 to 2024-09-3012,063,971USD274
2023-07-01 to 2023-09-303,615,020USD92
2023-01-01 to 2023-09-3010,848,611USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2024-07-01 to 2024-09-30139,840USD92
2024-01-01 to 2024-09-30450,194USD274
2023-07-01 to 2023-09-30164,595USD92
2023-01-01 to 2023-09-30484,094USD273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2024-01-01 to 2024-09-30622,790USD274
2023-01-01 to 2023-09-30559,805USD273

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2024-07-01 to 2024-09-3057,731USD92
2024-01-01 to 2024-09-30172,596USD274
2023-07-01 to 2023-09-3025,236USD92
2023-01-01 to 2023-09-3075,708USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2024-07-01 to 2024-09-30629,201USD92
2024-01-01 to 2024-09-301,766,572USD274
2023-07-01 to 2023-09-30503,192USD92
2023-01-01 to 2023-09-301,180,988USD273

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2024-01-01 to 2024-09-304,456,827USD274
2023-01-01 to 2023-09-304,136,152USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-1,950,885USD274
2023-01-01 to 2023-09-30-343,054USD273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-1,278,208USD274
2023-01-01 to 2023-09-306,130,592USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-473,820USD274
2023-01-01 to 2023-09-30519,648USD273

Inspect the source

Entity
IRADIMED CORPORATION / CIK 0001325618
Captured
2026-09-20T07:52:33.517Z
SEC response SHA-256
1217db54631fdc625eb836a9c89fbf1ed157044af9ce59b6e200421c6d8ca994

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001325618.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))